Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-2-14
pubmed:databankReference
pubmed:abstractText
Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M. Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket. The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors. Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib. Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude. The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance. Crystallographic analysis of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation. We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-11567148, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-12130516, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-12196540, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-12204532, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15118073, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15118125, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15272157, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15284455, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15299926, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15329413, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15374980, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15464447, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15572765, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15715478, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15728811, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15737014, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-15897464, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-16046538, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-16140912, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-16187797, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-16231326, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-16258541, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-16364841, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-16777603, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-16857803, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-16912195, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17020982, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17085664, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17097564, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17349580, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17405897, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17495523, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17613438, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17671201, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17726540, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-17922005, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-2432397, http://linkedlifedata.com/resource/pubmed/commentcorrection/18227510-9757107
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1091-6490
pubmed:author
pubmed:issnType
Electronic
pubmed:day
12
pubmed:volume
105
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2070-5
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
pubmed:affiliation
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural